[go: up one dir, main page]

AR063043A1 - Composicion farmaceutica de olanzapina - Google Patents

Composicion farmaceutica de olanzapina

Info

Publication number
AR063043A1
AR063043A1 ARP070104301A ARP070104301A AR063043A1 AR 063043 A1 AR063043 A1 AR 063043A1 AR P070104301 A ARP070104301 A AR P070104301A AR P070104301 A ARP070104301 A AR P070104301A AR 063043 A1 AR063043 A1 AR 063043A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
olanzapina
olanzapine
excipient
anhydrous lactose
Prior art date
Application number
ARP070104301A
Other languages
English (en)
Inventor
Niels Osinga
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of AR063043A1 publication Critical patent/AR063043A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Composicion farmacéutica de olanzapina tal como una tableta preparada utilizando lactosa anhidra como excipiente. Proceso.
ARP070104301A 2006-09-29 2007-09-28 Composicion farmaceutica de olanzapina AR063043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82760706P 2006-09-29 2006-09-29

Publications (1)

Publication Number Publication Date
AR063043A1 true AR063043A1 (es) 2008-12-23

Family

ID=39182376

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104301A AR063043A1 (es) 2006-09-29 2007-09-28 Composicion farmaceutica de olanzapina

Country Status (4)

Country Link
US (1) US20080138409A1 (es)
AR (1) AR063043A1 (es)
CL (1) CL2007002807A1 (es)
WO (1) WO2008037502A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
WO2012153347A2 (en) * 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
JP2014218472A (ja) * 2013-05-10 2014-11-20 エルメッド エーザイ株式会社 オランザピン乃至その塩含有錠剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2212281C3 (de) * 1972-03-14 1978-11-18 Hag Ag Verfahren zur entcoffeinierung von rohkaffee
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CA2266448A1 (en) * 1996-09-24 1998-04-02 Eli Lilly And Company Coated particle formulation
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
SI21303A (sl) * 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
EP1709053B1 (en) * 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (en) * 2005-08-17 2008-05-14 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions

Also Published As

Publication number Publication date
US20080138409A1 (en) 2008-06-12
CL2007002807A1 (es) 2008-04-11
WO2008037502A3 (en) 2008-05-22
WO2008037502A2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
CL2011002222A1 (es) Metodo para preparar una proteina biologica condicionalmente activa; metodo para preparar un modificador condicionalmente activo de respuesta biologica.
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
EP2329812A4 (en) Film-coated scored tablet
TW200806280A (en) Pharmaceutical compositions
IN2012DN01968A (es)
MX2011011136A (es) Eteres diarilicos.
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
PL2247602T3 (pl) Pochodne O-glukuronido-adamantylowe jako inhibitory dipeptydylopeptydazy IV do leczenia cukrzycy
EA201190319A1 (ru) Твердая фармацевтическая композиция, содержащая ривароксабан
BR112012011328A2 (pt) inibidores de akt
BRPI0921507A2 (pt) composição, método de preparação de um excipiente, comprimido farmacêutico e método de preparação do mesmo
IN2014CN03597A (es)
AP2757A (en) Process for preparation of HIV protease inhibitors
GEP20094784B (en) Sustained release pharmaceutical formulations
PL2217219T3 (pl) Podjęzykowa musująca tabletka progesteronu w połączeniu z cyklodekstryną
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
MX2012003488A (es) Proceso para la elaboracion de n-acil-bifenil-alanina.
AR063043A1 (es) Composicion farmaceutica de olanzapina
GB2458593C (en) Anthelmintic tablet formulations
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
SG136920A1 (en) Process for producing methionine

Legal Events

Date Code Title Description
FB Suspension of granting procedure